- Raised funding round, Jan 2017
About
ViruCure Therapeutics is a biotechnology company that develops NADAV, an oncolytic Newcastle disease virus (NDV) platform for the treatment of a wide range of cancer types. The NADAV technology works through the highly selective, replicative, and safe oncolytic effect of NDV in humans. The proprietary NDV strain specifically targets cancerous cells and then replicates itself, creating progeny viruses, which then target and infect others nearby, as well as distal cancerous cells (metastases), throughout the body. NADAV appears to work by causing cell death of the infected tumor cells and by triggering the host's immune response towards the cancerous cells by activating the anti-tumoral immune response. This oncolytic amplification effect is achieved with very low toxicity because NADAV specifically destroys the tumor cells and does not attack normal tissues. Furthermore, since NDV is an avian virus, it has not exhibited any pathological effects or severe illnesses in humans in over 40 years of research. The initial targeted therapies for the platform are currently glioblastoma multiforme and lung cancer patients. This proprietary NDV technology was developed at the Hebrew University of Jerusalem.
Funding history · 1 round · — total
Q&A
- What is ViruCure Therapeutics' primary focus?
- ViruCure Therapeutics is a biotechnology company focused on developing NADAV, an oncolytic Newcastle disease virus (NDV) platform for treating various cancer types.
- What is the current status of ViruCure Therapeutics?
- ViruCure Therapeutics is currently inactive, having ceased operations in December 2024.
- When was ViruCure Therapeutics founded?
- ViruCure Therapeutics was founded in September 2016.
- What is the employee count for ViruCure Therapeutics?
- ViruCure Therapeutics has 1-10 employees.
- What is the initial target for ViruCure Therapeutics' NADAV platform?
- The initial targeted therapies for the NADAV platform are glioblastoma multiforme and lung cancer patients.
- Where was the proprietary NDV technology developed?
- The proprietary NDV technology utilized by ViruCure Therapeutics was developed at the Hebrew University of Jerusalem.
- What is ViruCure Therapeutics' primary sector?
- ViruCure Therapeutics' primary sector is Health Tech & Life Sciences.
- What is the product stage of ViruCure Therapeutics' technology?
- The product stage of ViruCure Therapeutics' technology is clinical trial.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/27225236 |
Identifiers & details
| Founded | 2016-9 |
|---|---|
| Employees (exact) | 1 |
| Status reason | Non Active, Dec 2024 ceased to operate |